A temporary federal cushion that has quietly held down Medicare drug-plan premiums for two years is being pulled away, and the effect will show up in millions of monthly bills. Federal officials announced on July 28, 2026 that the program shielding stand-alone drug plans from premium swings will end after December 31, 2026. For 2027, most Part D enrollees will pay more, and for nearly half of them the increase lands in a range big enough to notice.
The Part D Premium Stabilization Demonstration is ending
The cushion has a bureaucratic name: the Part D Premium Stabilization Demonstration. It was a voluntary program the federal government launched in 2025 to keep drug-plan premiums from lurching after the Inflation Reduction Act redesigned the Part D benefit. The Centers for Medicare & Medicaid Services paid insurers to blunt those swings, at a cost of roughly $9.8 billion across 2025 and 2026, and it covered about 25 million people enrolled in standalone drug plans. As the Center for Medicare Advocacy explains, that support is now scheduled to disappear at the end of 2026, which removes the discount that has been quietly baked into premiums.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Roughly three in four enrollees will pay more
The federal numbers describe the shape of the increase. About 75% of Part D enrollees will see their premiums rise for 2027. Roughly 30% will see a small bump of less than $10 a month. The larger group, about 45% — “nearly half” — will see increases that fall largely in the $11 to $20 per month range. Put another way, only about a quarter of enrollees will avoid an increase entirely, while the typical affected household is looking at an extra $11 to $20 each month, or something on the order of $130 to $240 over a full year.
Those figures are averages across a very large group, and any single plan can move more or less than the middle of the pack. But the direction is one-way for most people: up. A household that has grown comfortable with a low premium over the past two years should not assume that number carries into January.
Why the underlying bid is climbing about 24%
Behind the premiums sits a wholesale figure called the national average monthly bid, which reflects what plans expect it will cost to provide the standard drug benefit. For 2027, that bid is set at $296.05, a jump of roughly 24% from the prior year, as detailed by Managed Healthcare Executive. The bid is not the premium a person pays, but it is a major input into it, and a double-digit increase in that base number is a large part of why plan premiums are rising. With the stabilization payments gone, more of that higher cost flows through to enrollees instead of being absorbed by the federal demonstration.
Comparing plans during Open Enrollment is the lever
The single most effective response is also the most ordinary one: compare drug plans during Medicare’s Open Enrollment period, which runs October 15 to December 7, with any new plan taking effect January 1. Premiums are not moving in lockstep, so a household that shops can often find a plan that softens or offsets the increase, especially if its list of prescriptions has changed over the past year. The federal government’s overview of Part D drug coverage is the neutral starting point, and Medicare’s Plan Finder lets a person enter their exact medications to see total expected costs, not just the premium.
The mistake to avoid is auto-renewing without checking. Plans that were competitive in 2026 may not be in 2027, and the cheapest premium is not always the cheapest plan once a household’s actual drug list and copays are factored in. Comparing on total annual cost — premium plus expected out-of-pocket spending on the specific drugs a person takes — is what turns a rising-premium year into a manageable one.
What to watch for before January
Every plan mails an Annual Notice of Change explaining what is different for the coming year, and it typically arrives by late September. That notice is where a rising premium, a change to the drug formulary, or a shift in copays will be spelled out for a specific plan. Reading it, then running the numbers in Plan Finder before December 7, is the difference between absorbing an avoidable increase and steering around it. With the federal cushion gone and the base cost climbing, 2027 is a year when doing nothing has a price.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
